Search Results

You are looking at 121 - 130 of 485 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Surviving the Perfect Storm: An RVU-Based Model to Evaluate the Continuing Impact of MMA on the Practice of Oncology

David M. Dunning and Thomas A. Paivanas

:// . Accessed November 2005 . 10. Langer CJ Leighton JC Comis RL . Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response, and survival analysis . J Clin

Full access

Oncology Research Program

pharmacokinetics of carboplatin and pralatrexate used in combination Contact: Marcela G. del Carmen, MD, MPH • 617-724-4800 • Identifier: NCT01188876 Neoadjuvant Weekly nab-Paclitaxel (Abraxane) Plus

Full access

Oncology Research Program

scientific peer-review process and are overseen by the ORP. NCCN studies funded through the grant mechanism are highlighted below. Neoadjuvant Weekly nab-Paclitaxel (Abraxane) Plus Carboplatin Followed by Doxorubicin Plus Cyclophosphamide With

Full access

Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib

Vinod Ravi, Eric M. Sanford, Wei-Lien Wang, Jeffrey S. Ross, Naveen Ramesh, Andrew Futreal, Shreyaskumar Patel, Phillip J. Stephens, Vincent A. Miller, and Siraj M. Ali

disease. The patient was initially treated with paclitaxel at 80 mg/m 2 weekly; however, he was unable to tolerate paclitaxel weekly without a treatment break. He was therefore maintained on paclitaxel at the 80 mg/m 2 dose, cycling 2 weeks on and 1 week

Full access

Optimal Treatment of Unresectable Nonmelanoma Skin Cancers

Thomas Olencki

the combination of high-dose celecoxib and paclitaxel, cetuximab, and erlotinib. However, he noted that further research is needed to confirm early encouraging findings for these agents. The benefits of high-dose celecoxib ( Figure 1 ) and paclitaxel

Full access

NCCN Guidelines Updates: Pancreatic Cancer

Margaret A. Tempero

-resistant, and patients suffer from debilitating cytokine-mediated symptoms.” Current Treatment of Metastatic Disease Remains Challenging First-line treatment regimens remain FOLFIRINOX and gemcitabine/albumin-bound nab-paclitaxel, and for patients with BRCA1

Full access

Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer

Min Huang, Joyce O’Shaughnessy, Jing Zhao, Amin Haiderali, Javier Cortes, Scott Ramsey, Andrew Briggs, Vassiliki Karantza, Gursel Aktan, Cynthia Z. Qi, Chenyang Gu, Jipan Xie, Muhan Yuan, John Cook, Michael Untch, Peter Schmid, and Peter A. Fasching

4 RCTs, carboplatin in 3 RCTs, and nab-paclitaxel, everolimus, and anthracycline in 1 RCT each. Different pCR definitions were used across trials, of which ypT0/is ypN0 was the most common. The characteristics of the included trials are listed in

Full access

Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected Pancreatic Cancer

Pranav Murthy, Mazen S. Zenati, Samer S. AlMasri, Annissa DeSilva, Aatur D. Singhi, Alessandro Paniccia, Kenneth K. Lee, Richard L. Simmons, Nathan Bahary, Michael T. Lotze, and Amer H. Zureikat

gemcitabine + nab-paclitaxel with or without hydroxychloroquine ( identifier: NCT01978184 ). 43 In patients with available specimens, an enzyme-linked immunosorbent assay (ELISA; Caymen Chemical Clone 11D3) measuring citrullinated histone H

Full access

Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial Cancer

Sushmita Gordhandas, William A. Zammarrelli III, Eric V. Rios-Doria, Angela K. Green, and Vicky Makker

standard first-line (1L) therapy for newly diagnosed advanced/recurrent EC regardless of molecular subtype consists of carboplatin/paclitaxel (TC) chemotherapy with or without primary surgical cytoreduction. Key clinical trials assessing systemic therapy

Full access

Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem, Joseph Chao, Carlos Corvera, Prajnan Das, Crystal S. Denlinger, Peter C. Enzinger, Paul Fanta, Farhood Farjah, Hans Gerdes, Michael Gibson, Robert E. Glasgow, James A. Hayman, Steven Hochwald, Wayne L. Hofstetter, David H. Ilson, Dawn Jaroszewski, Kimberly L. Johung, Rajesh N. Keswani, Lawrence R. Kleinberg, Stephen Leong, Quan P. Ly, Kristina A. Matkowskyj, Michael McNamara, Mary F. Mulcahy, Ravi K. Paluri, Haeseong Park, Kyle A. Perry, Jose Pimiento, George A. Poultsides, Robert Roses, Vivian E. Strong, Georgia Wiesner, Christopher G. Willett, Cameron D. Wright, Nicole R. McMillian, and Lenora A. Pluchino

preoperative chemotherapy or surgery alone in patients with locoregional esophageal cancer. 61 – 67 Results from the multicenter phase III randomized CROSS trial, the largest trial in its class, showed that preoperative chemoradiation with paclitaxel and